Chunk #24 — Current Status of Drug Labeling and Pharmacogenomic Testing Guidelines — Labeling for Valproic Acid

Source

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Embedded

yes

Text

additional evaluation.23 Although there are genetic variants in the CPS1 and OTC genes that are associated with UCDs, genotyping for these variants before the initiation of valproic acid therapy is not recommended at this time. This is perhaps due to the general early recognition of these disorders, which would theoretically result in a relatively low number of previously unidentified patients discovered as part of clinical genetic testing.